Advicenne (Euronext Growth Paris: ALDVI), a specialty pharmaceutical company focused on rare renal diseases, announced on Monday that its proprietary drug ADV7103 has secured Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for cystinuria treatment.
ADV7103 is one of the few drugs with Orphan Drug status for both cystinuria and distal Renal Tubular Acidosis (dRTA) in the United States. Cystinuria, affecting around 30,000 patients in the US, presents a pressing medical need due to complications such as kidney stones and renal function impairment.
A fixed combination of sustained-release potassium citrate and potassium bicarbonate, ADV7103 offers a promising treatment approach for cystinuria, potentially addressing significant unmet needs in North America and Europe. With approximately 40,000 patients affected in Europe and similar numbers in the US, ADV7103's approval could mark a substantial advancement in cystinuria management, providing patients with a novel therapeutic option.
Advicenne anticipates pursuing partnerships to advance development and commercialisation efforts for ADV7103 in both cystinuria and dRTA indications.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024